Literature DB >> 7957266

Beta-lactam resistance among Escherichia coli and Klebsiella species blood culture isolates in Finnish hospitals. Finnish Study Group for Antimicrobial Resistance.

T Arstila1, H Auvinen, P Huovinen.   

Abstract

The aim of this study was to investigate beta-lactam resistance in Escherichia coli and Klebsiella spp. blood culture isolates in Finland. Special attention was given to extended-spectrum beta-lactamases. A total of 566 Escherichia coli and 108 Klebsiella spp. blood culture isolates were collected from hospitals throughout Finland and their susceptibility to beta-lactam antibiotics studied. Twenty percent of Escherichia coli and 69% of Klebsiella spp. strains were resistant to ampicillin. The mechanisms of resistance were studied by hybridization, isoelectric focusing and the clavulanate double-disk potentiation test. Of the ampicillin-resistant Escherichia coli strains, 83% produced TEM-1. Of the ampicillin-resistant Klebsiella spp. strains, 43% produced SHV-1. Only nine Escherichia coli and three Klebsiella spp. isolates were resistant to cefuroxime (MIC > or = 32 micrograms/ml), and none were resistant to third-generation cephalosporins. These data were compared with cefuroxime and third-generation cephalosporin consumption levels in Finnish hospitals. Although the use of cephalosporins is far more extensive in Finland than in other Scandinavian countries, none of the isolates produced extended-spectrum beta-lactamases. In conclusion, resistance to cefuroxime has remained rare in Finland, and cefuroxime is still an alternative to third-generation cephalosporins in the treatment of septicemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957266     DOI: 10.1007/BF01974636

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests.

Authors:  K S Thomson; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  The frequency of extended-spectrum beta-lactamases in isolates of Klebsiella pneumoniae.

Authors:  G Katsanis; G Jacoby
Journal:  J Antimicrob Chemother       Date:  1992-03       Impact factor: 5.790

3.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 4.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  Detection of plasmid-mediated beta-lactamases with DNA probes.

Authors:  S Huovinen; P Huovinén; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

6.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

7.  Aminoglycoside resistance among blood culture isolates.

Authors:  P Huovinen; P Grönroos; E Herva; M L Katila; M L Klossner; O V Renkonen; P Toivanen
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

8.  Analysis of beta-lactamase production in ampicillin-resistant Escherichia coli isolated from blood cultures 1983-1989.

Authors:  T Arstila; S Huovinen; P Huovinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

9.  Evaluation of plasmid-encoded beta-lactamase resistance in Escherichia coli blood culture isolates.

Authors:  S Huovinen; P Huovinen; K Torniainen; G A Jacoby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

Review 10.  beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact.

Authors:  C C Sanders; W E Sanders
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.